Home > Insider Trading > Filing (0001181431-13-018836)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1216917	Michael Bigham	C/O Abingworth Management Inc 890 Winter Street, Suite 150 Waltham MA 02451		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-03-20	5,000	$5.17	5,000	No	4	P	Indirect	By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
Common Stock	Acquisiton	2013-03-20	5,000	$5.20	5,000	No	4	P	Indirect	By Cabot Forbes Bigham Trust U/A DTD 10/11/1996
Common Stock	Acquisiton	2013-03-20	10,000	$5.26	10,000	No	4	P	Indirect	By Michael F Bigham CRUT U/A DTD 11/23/1994
Common Stock	Acquisiton	2013-03-22	15,000	$5.65	25,000	No	4	P	Indirect	By Michael F Bigham CRUT U/A DTD 11/23/1994

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
No	4	P	Indirect	By Cabot Forbes Bigham Trust U/A DTD 10/11/1996
No	4	P	Indirect	By Michael F Bigham CRUT U/A DTD 11/23/1994
No	4	P	Indirect	By Michael F Bigham CRUT U/A DTD 11/23/1994

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Director Stock Option (Right to Buy)	$7.90	2014-02-05	2023-02-05	8,722	8,722	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2023-02-05	8,722	8,722	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.11 to $5.20, inclusive. The Reporting Person undertakes to provide to any security holder of Supernus Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4).
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.17 to 5.20, inclusive.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.18 to 5.49, inclusive.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.53 to 5.68, inclusive.